BUZZ-Hims and Hers falls as US shortage of Novo's weight loss drug is resolved

Reuters2025-02-21

BUZZ-Hims and Hers falls as US shortage of Novo's weight loss drug is resolved

** Shares of telehealth firm Hims and Hers HIMS.N, which offers compounded versions of weight-loss drugs, fall 20.4% to $52.8

** The U.S FDA says that a shortage of Novo Nordisk's NOVOb.CO weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved as per the agency's website

** The resolution could restrict how telehealth programs offer cheaper versions known as compounded drugs

** For HIMS and other compounders "this development starts the clock on having unfettered market access" to Novo's drugs, says brokerage Leerink Partners

** It will be critical to understand HIMS' legal pathway to selling personalized doses for semaglutide - since it is the primary way it can continue selling the drug, Leerink added

** US government regulations allow compounded versions of a branded drug to be sold to meet demand if the drug is in shortage

** Stock has risen nearly seven-fold in the past 12 months

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2513291974?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-21 23:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2513291974","market":"us","top_or_hot":-1,"title":"BUZZ-Hims and Hers falls as US shortage of Novo's weight loss drug is resolved","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Hims and Hers falls as US shortage of Novo's weight loss drug is resolved </title></head><body><p>** Shares of telehealth firm Hims and Hers <span>HIMS.N</span>, which offers compounded versions of weight-loss drugs, fall 20.4% to $52.8 </p><p>** The U.S FDA says that a <span>shortage</span> of Novo Nordisk's <span>NOVOb.CO</span> weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved as per the agency's website </p><p>** The resolution could restrict how telehealth programs offer cheaper versions known as compounded drugs</p><p>** For HIMS and other compounders \"this development starts the clock on having unfettered market access\" to Novo's drugs, says brokerage Leerink Partners </p><p>** It will be critical to understand HIMS' legal pathway to selling personalized doses for semaglutide - since it is the primary way it can continue selling the drug, Leerink added</p><p>** US government regulations allow compounded versions of a branded drug to be sold to meet demand if the drug is in shortage</p><p>     ** Stock has risen nearly seven-fold in the past 12 months  </p><p> (Reporting by Padmanabhan Ananthan)</p><p> ((Padmanabhan.Ananthan@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Hims and Hers falls as US shortage of Novo's weight loss drug is resolved</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Hims and Hers falls as US shortage of Novo's weight loss drug is resolved\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-21 23:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Hims and Hers falls as US shortage of Novo's weight loss drug is resolved </title></head><body><p>** Shares of telehealth firm Hims and Hers <span>HIMS.N</span>, which offers compounded versions of weight-loss drugs, fall 20.4% to $52.8 </p><p>** The U.S FDA says that a <span>shortage</span> of Novo Nordisk's <span>NOVOb.CO</span> weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved as per the agency's website </p><p>** The resolution could restrict how telehealth programs offer cheaper versions known as compounded drugs</p><p>** For HIMS and other compounders \"this development starts the clock on having unfettered market access\" to Novo's drugs, says brokerage Leerink Partners </p><p>** It will be critical to understand HIMS' legal pathway to selling personalized doses for semaglutide - since it is the primary way it can continue selling the drug, Leerink added</p><p>** US government regulations allow compounded versions of a branded drug to be sold to meet demand if the drug is in shortage</p><p>     ** Stock has risen nearly seven-fold in the past 12 months  </p><p> (Reporting by Padmanabhan Ananthan)</p><p> ((Padmanabhan.Ananthan@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4207","symbol_name":"综合性银行","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nL3N3PC1D2:1","article_id":"2513291974","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2513291974","pubTimestamp":1740151429,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Hims and Hers falls as US shortage of Novo's weight loss drug is resolved ** Shares of telehealth firm Hims and Hers HIMS.N, which offers compounded versions of weight-loss drugs, fall 20.4% to $","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4207":"综合性银行","HIMS":"Hims & Hers Health Inc.","BK4211":"区域性银行","BK4589":"SVB概念","BK4196":"保健护理服务","BK4588":"碎股","BK4585":"ETF&股票定投概念","SIVBQ":"硅谷银行"},"translate_title":"随着美国Novo减肥药短缺问题得到解决，BUZZ-Hims and Hers股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SIVBQ":0.9,"HIMS":0.9},"content_text":"BUZZ-Hims and Hers falls as US shortage of Novo's weight loss drug is resolved ** Shares of telehealth firm Hims and Hers HIMS.N, which offers compounded versions of weight-loss drugs, fall 20.4% to $52.8 ** The U.S FDA says that a shortage of Novo Nordisk's NOVOb.CO weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved as per the agency's website ** The resolution could restrict how telehealth programs offer cheaper versions known as compounded drugs** For HIMS and other compounders \"this development starts the clock on having unfettered market access\" to Novo's drugs, says brokerage Leerink Partners ** It will be critical to understand HIMS' legal pathway to selling personalized doses for semaglutide - since it is the primary way it can continue selling the drug, Leerink added** US government regulations allow compounded versions of a branded drug to be sold to meet demand if the drug is in shortage     ** Stock has risen nearly seven-fold in the past 12 months   (Reporting by Padmanabhan Ananthan) ((Padmanabhan.Ananthan@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2513291974","isCrawlerRequest":true}